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Existing prediction algorithms for the identification of heart failure (HF) patients at high risk of 
readmission or death after hospital discharge are only modestly effective. We sought to validate a 
recently developed predictive model of 30-day readmission or death in HF using an Australia-wide 
sample of patients. This study used data from 1046 HF patients at teaching hospitals in five Australian 
capital cities to validate a predictive model of 30-day readmission or death in HF. Besides standard 
clinical and administrative data, we collected data on individual socio-demographic and socio-
economic status, mental health (PHQ-9 and GAD-7 score), cognitive function (MoCA score), and 2D 
echocardiograms.  The original sample used to develop the predictive model and the validation 
sample had similar proportions of patients with an adverse event within 30 days (30% vs 29%, 
p=0.35) and 90 days (52% vs 49%, p=0.36). Applying the predicted risk score to the validation 
sample provided very good discriminatory power (C-statistic=0.77) in prediction of 30-day 
readmission or death. This discrimination was greater for predicting 30-day death (C-statistic=0.85) 
than for predicting 30-day readmission (C-statistic=0.73). There was little difference in the 
performance of the predictive model among patients with either LVEF<40% or LVEF≥40%, but an 
attenuation in discrimination when used to predict longer-term adverse outcomes. In conclusion, our 
findings confirm the generalizability of the predictive model that may be a powerful tool for targeting 
high-risk HF patients for intensive management. 
Key words: algorithm; mortality; rehospitalisation; risk score; quality. 
  





Heart failure (HF) is the leading cause of hospitalization and re-hospitalization for adults aged >65 
years.
1, 2
 High readmission rates following an index HF admission continue to be a problem in many 
countries and across different racial and ethnic groups.
3-5
 In Australia, approximately 30,000 patients 
are diagnosed with HF each year and the costs for HF readmissions exceed $1 billion annually.
6
 
Readmission for HF is a powerful independent predictor of death among patients with HF, as well as 
being a serious health economic problem.
7, 8
 Readmissions shortly after discharge are expensive and 
often considered preventable.
2
  Recently, all-cause mortality and readmission within 30 days of a 
prior hospitalization for HF has emerged as a major focus of quality improvement and payment 
reform.
9
 However, despite a number of interventions, readmission rates have been difficult to 
reduce.
10
 This may be partly due to failure to target the interventions to patients at high risk of 
readmission. Financial constraints also become a problem when these interventions are applied 
indiscriminately to all patients.
11
 We have recently developed a predictive model for 30-day 
readmission or death in HF,
12
 which combined both clinical and non-clinical factors to provide 
excellent discriminatory power (C-statistic 0.82). We now aim to validate this predictive model on an 
Australia-wide cohort of HF patients. 
 
Methods 
This study used data from 1046 consecutive HF patients who were recruited during 2015–
2017 in most Australian States (Tasmania, Victoria, New South Wales, Queensland and South 
Australia). Patients were identified as eligible if their primary diagnosis was confirmed as HF by their 
treating physicians. Exclusion criteria were: <18 years of age, inability to provide written consent, 
moderate or worse primary mitral or aortic valve disease, concomitant unstable angina pectoris or 
acute myocardial infarction as the primary cause of admission, cardiac device malfunction, infective 
endocarditis, patients with left ventricular assist device, patients with potentially reversible left 
ventricular (LV) dysfunction including post-partum, alcoholic cardiomyopathy and hyperthyroidism, 
and concomitant terminal non-cardiac illnesses that could influence 12 month prognosis. All patients 





provided written consent. The study was approved by the Tasmanian Human Research Ethics 
Committee. 
 Clinical data included past medical history (including chronic kidney disease based on 
discharge coding), medications, physical measurements and blood tests before discharge. Standard 
physical measurements included body weight, blood pressure, heart rate, respiratory rate, and 
electrocardiography. Two-dimensional echocardiographic parameters included LV ejection fraction 
(EF), LV volume index, left atrial volume index, right atrial pressure, pulmonary arterial systolic 
pressure and estimated LV filling pressure (E/e’), using standard techniques and procedures following 
the American Society of Echocardiography guideline.
13
 Biochemical measurements included troponin 
I, C-reactive protein, albumin, blood urea nitrogen, sodium, creatinine, hematocrit, hemoglobin, 
cholesterol, and B-type natriuretic peptide. HF functional class was defined using the New York Heart 
Association (NYHA) Class. The Charlson comorbidity index was calculated as previously 
described.
14
 Patients were considered to have a history of life-threatening arrhythmia if they had an 
episode of ventricular tachycardia or fibrillation shortly prior to (as part of the reasons for the baseline 
admission) or during their admission with HF. Patients’ cognitive function was assessed before 
discharge by trained personnel using the Montreal Cognitive Assessment (MoCA). The MoCA 
examines different domains of cognition and was designed to detect mild cognitive impairment with 
excellent sensitivity (90%) and specificity (87%).
15
 A MoCA score <26 was used to define mild 
cognitive impairment. Patients who did not finish college/grade 12 had one point added as instructed 
in the MoCA protocol. Depression was assessed using the Patient Health Questionnaire (PHQ-9), with 
cut-points of 5, 10 and 15 used to define mild, moderate and moderately severe/severe depression 
respectively.
16
  Anxiety was assessed using the Generalized Anxiety Disorder scale (GAD-7), with 
cut-points of 5, 10 and 15 used to define mild, moderate and severe anxiety respectively.  
 Non-clinical data included age, sex, language background, marital status, living alone, 
education, residential address, medical insurance, and any home health care services provided. 
Socioeconomic status based on residential postcode was derived using the Australian Bureau of 
Statistics Index of Relative Socioeconomic Disadvantage.
17
 The remoteness index - based on 





residential address - reflects how far away a geographical area is from service towns of different sizes 
based on road distance.
18
 
 This model was developed to predict 30-day all-cause readmission or death in HF.
12
 It 
incorporates social history (living alone or with others), medical data (life-threatening arrhythmia, 
heart rate, NYHA classification, and whether being discharged in winter), cognitive function, mental 
health, echocardiographic data (left atrial volume index, right atrial pressure) and lab test (blood urea 
nitrogen, serum albumin). The development of this model has been previously described.
12
 Briefly, 
logistic regression was used to determine and rank the variables that served as best predictors of 
readmission or death. A predictor was included in the final model if it contributed ≥0.01 unit to the 
area under the curve.  
 For descriptive statistics, we reported categorical variables as the number of patients with 
percentages, and continuous variables as median with interquartile range. A score of predicted risk 
was calculated for each patient in the validation sample using the predictive model coefficients and 
intercept that were previously described in the original publication.
12
 These predicted scores were then 
converted to percentages to reflect how likely a patient was going to have an adverse outcome. We 
also used this predicted score to estimate the area under the curve and compared against the observed 
risk of having the adverse outcomes. Plots of the predicted risk vs. the observed risk outcomes were 
also used to evaluate the model’s calibration. Youden’s index was used to define the optimal cut-point 
of the risk score and to accordingly calculate its sensitivity and specificity.  
 
Results 
Table 1 compares baseline characteristics between patients in the original sample whose data 
were used to develop the predictive model and patients in the validation sample. The two samples of 
patients had similar age at admission and similar male-female ratio. However, there was significantly 
lower proportion of patients in the validation sample living outside of a major city, having a history of 
smoking and having a history of arrhythmia. This may explain for the lower use of antiarrhythmic 
medication in the validation sample compared with that in the original sample, despite of similar use 
of other HF medications. While the proportion of HF patients with reduced LVEF was similar, the 





validation sample had more patients with more severe HF (higher NYHA class) and more dilated LV 
than the original sample. There was no significant difference in cognitive function and other 
comorbidities between the two samples. 
In general, the two samples had no significant difference in short-term adverse outcomes after 
discharge. Approximately one in three patients in either sample was readmitted or dead within 30 
days of discharge, and one in two patients was readmitted or dead within 90 days (Table 2). Table 3 
illustrates how to calculate predicted risk using the coefficients and intercept from the predictive 
model. The average risk score of the original sample (32%±27%) and the validation sample 
(34%±27%) were similar (p=0.42). 
Figure 1 shows the area under the curve when predicting adverse outcomes within 30 days of 
discharge. Applying the predicted risk score to the validation sample provided very good 
discriminatory power (C-statistic=0.77 [95% CI: 0.74, 0.81]) in prediction of the composite outcome 
within 30 days of discharge in HF. This discrimination was greater for predicting 30-day death (C-
statistic=0.85 [95% CI: 0.79, 0.91]) than for predicting 30-day readmission (C-statistic=0.73 [95% CI: 
0.69, 0.77]). Figure 2 demonstrates little difference in the performance of the predictive model in 
patients with either LVEF<40% or LVEF≥40%. However, there was an attenuation in discriminatory 
power of the model when used to predict outcomes within 90 days of discharge (as shown in Figure 
3). 
Figure 4 shows very good calibration of the predictive model with observed events by 
plotting predicted vs. observed risk of 30-day readmission or death within the risk deciles. Although 
slightly overestimating the absolute values of observed risks, the predictive model has shown 
excellent accuracy in risk stratification among HF patients (Figure 5). 
Youden’s index was used to define optimal cut-points of the risk score. A predicted score of 
44% risk (sensitivity 65%, specificity 81%) appeared to be optimal for 30-day readmission or death, 
and a predicted score of 29% risk (sensitivity 64%, specificity 65%) for 90-day readmission or death. 
 
Discussion 





The short-term risks of death or readmission after a hospitalization with HF remain very high. 
These outcomes are important for health care quality improvement, and are a central focus for 
patients, health care providers, taxpayers and policy makers. Effective targeting of disease 
management programs is likely to reduce readmissions at the same time as saving money. This, 
however, requires a reliable tool to identify high-risk patients who are most likely to benefit from the 
interventions.  
This study used an Australia-wide sample of HF patients to validate a previously developed 
risk score of 30-day readmission or death. This model has shown excellent external validation and 
calibration, and may be used to predict both short-term mortality and readmission with very good 
discrimination. The availability of this risk score will facilitate targeting high-risk HF patients for 
intensive management, and therefore help to reduce readmissions. High-intensity home visiting 
programs may reduce all-cause readmission or death within 30 days of discharge among HF patients. 
Such programs are certainly expensive. Although a more detailed cost-effective analysis is required, 
the availability of our risk score may allow high-risk HF patients to be targeted for these programs 
and reduce cost. There was little difference in the performance of this model in predicting outcomes 
for patients with either reduced or preserved LVEF. The discriminatory power of the model was 
attenuated when used to predict longer-term adverse outcomes.  
A systematic review of readmission risk scores in 2008 showed that the strongest prediction 
models provided only poor discrimination (C-statistic<0.6) in predicting readmissions among HF 
patients.
19
 Several risk scores for the prediction of HF readmission have been developed and 
validated.
3, 20-24
 Despite the use of large samples, these models - which mainly consist of standard 
clinical parameters and comorbidities – are only modestly effective in predicting short-term outcomes 
in HF. These findings suggest that some important determinants of readmission were missing in the 
previous models. Of these previous models, the one developed by Amarasingham
24
 combined a range 
of clinical and non-clinical factors (some of which are similar to those of ours such as living 
arrangement and mental health) and is therefore most discriminative (C-statistic 0.72). However, this 
model used data from the electronic medical record, and did not include echocardiographic 





parameters and cognitive function that are shown to be very important for 30-day adverse outcomes in 
our study. This may explain their lower C-statistic than that of our prediction model – which, to the 
best of our knowledge, has the greatest discriminatory power so far reported for prediction of short-
term adverse outcomes among HF patients. 
These factors may include readiness for discharge, ability for self-care and family/social 
support. A discharge echocardiogram to assess the level of congestion may help to determine if a 
patient is ready for discharge. A cognitive function test reflects a patient’s ability for self-care, which 
is a key to health maintenance and adherence to treatment. Whether a patient is living alone, with 
family or in a nursing facility indicates how much support the patient may need. All these factors 
were incorporated in the model that we tested in this study, which resulted in a very good 
predictability of both 30-day readmission and 30-day death in HF. Our validation of the model using 
an Australia-wide cohort of HF patients further confirms its generalizability. 
Common clinical factors such as prescription of evidence-based medications or Charlson’s 
comorbidity index, which are known to be predictors of long-term adverse outcomes in HF, were 
associated with the outcome in univariable analysis. However, these associations became weaker in 
multivariable analysis and did not add incremental value to the discriminatory power of the prediction 
model. These findings suggest that readmission shortly after discharge may be driven, not only by 
quality of care or severity of disease, but also by other factors such as social or family support, 
cognitive function or mental health. 
Our findings support the importance of multidisciplinary care to reduce short-term adverse 
outcomes in HF patients. Some of the risk factors in the model are potentially reversible with 
appropriate care. Although limited data show that therapeutic interventions to improve cardiac 




 and exercise training
28
 might improve 
cognition in some HF patients,  it is likely that additional support and assistance would help most 
patients with poor cognitive function. Provision of greater nursing and medical attention to enhance 
adherence to treatment plan and medications may reduce short-term readmission and mortality risk 





among these high risk patients. Depression is also potentially modifiable with pharmaceutical and/or 
psychological treatment. Although the mechanism underlying the relationship between depression and 
readmission or death in HF is unknown, data have shown that differences in help-seeking behaviour,
29
 
health behaviour and treatment adherence
30
 may play a role. 
This study included a range of patients from a multicenter study of HF, which favors the 
generalizability of our findings. The prospective nature of this study allowed us to collect a wide 
range of potential predictors and avoid the known limitations of administrative codes as in 
retrospective studies. The very good discriminatory power from our external validation further 
confirms the applicability of the prediction model to an external HF population.  
Because of the use of a composite outcome, the prediction model could not differentiate 
strong predictors of one outcome from those of the other. However, the primary aim of this work was 
to develop a simple and feasible tool that can quickly and accurately stratify HF patients in the busy 
setting of clinical practice. This model has proven to have excellent discrimination for both 
readmission and mortality. Although the predicted risks appear to overestimate the absolute values of 
observed risk, they are strongly correlated and show consistent risk stratification among HF patients. 
Our sample however included mostly Caucasian patients, and validation of the model on other ethnic 
groups is required. 
In conclusion, short-term risk of readmission and death after hospitalization for HF remain 
very high. Preventing such events is complex and requires multidisciplinary efforts. Our previously 
developed predictive model – which had excellent external validation and calibration – may be a 
powerful tool for this purpose. The availability of this model will facilitate targeting high-risk HF 
patients for intensive management, and therefore may help to reduce readmissions. 
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Figure 1. Area under the curve of the predictive model with 30-day death (A), 30-day readmission 
(B) and the composite outcome (C) 
Figure 2. Area under the curve of the predictive model with 30-day readmission or death among 
patients with LVEF<40% (A) and LVEF≥40% (B). 
Figure 3. Area under the curve of the predictive model with 90-day death (A), 90-day readmission 
(B) and the composite outcome (C) 
Figure 4.  Calibration of the predictive model with observed events. The graph plots the predicted 
risk vs. observed 30-day readmission or death within the risk deciles (intercept 3.02, slope 0.79, R
2
 
96%, P<0.001).  
Figure 5. Accuracy of the predictive model for risk stratification among HF patients. There is a slight 
over-estimation of the absolute values of observed risks. 
  













Potential predictors Description Description p 
Age at admission (year) 75 [64, 83] 76 [67, 84] 0.72 
Men  236 (55%) 607 (58%) 0.78 
Completed education (≥ High school) 220 (52%) 523 (50%) 0.31 
Living alone 129 (30%) 366 (35%) 0.85 
Living outside of a major city 172 (40%) 345 (33%) 0.05 
Smoker (ever vs never) 301 (70%) 721 (69%) 0.75 
Solid organ tumor 30 (7%) 73 (7%) 0.97 
Diabetes mellitus     0.37 
Mild, without complications 125 (29%) 293 (28%)  
Complications/End-organ damage 51 (12%) 115 (11%)  
Life-threatening arrhythmia 39 (9%) 67 (6%) 0.003 
Cerebrovascular disease or stroke 51 (12%) 105 (10%) 0.13 
Discharge during winter 116 (27%) 261 (25%) 0.32 
Heart rate 75 [68, 86] 76 [68, 88] 0.50 
Charlson comorbidity index 7 [5, 9] 7 [6, 9] 0.74 
Chronic kidney disease 155 (36%) 377 (36%) 0.73 
Cardiac catheterization (ever vs never) 172 (40%) 408 (39%) 0.87 
NYHA class     <0.001 
Class II or under 241 (56%) 418 (40%)  
Class III 150 (35%) 408 (39%)  
Class IV 39 (9%) 220 (21%)  
LVEF < 40% 206 (48%) 481 (46%) 0.55 
Right atrial pressure (mmHg) 8 [3, 15] 8 [3, 15] 0.45 





Left atrial volume index (ml/m
2
) 42 [30, 60] 45 [34, 62] 0.77 
Pulmonary systolic pressure (mmHg) 38 [30, 48] 38 [30, 48] 0.52 
Left ventricular volume index (ml/m
2
) 56 [43, 80] 65 [47, 83] 0.001 
Blood urea nitrogen (mg/dL) 10.5 [7.6, 16.1] 10.1 [7.4, 15.1] 0.42 
B-type natriuretic peptide (pg/mL) 784 [416, 1723] 1352 [788, 3581] 0.003 
Serum albumin (g/dL) 35 [31, 38] 33 [30, 36] 0.36 
C-reactive protein (mg/L) 10.5 [5.0, 25.4] 13.0 [5.8, 29.0] 0.30 
Serum creatinine (µmol/L) 116 [90, 153] 112 [88, 152] 0.21 
MoCA score 23 [18, 26] 22 [17, 26] 0.69 
GAD-7 score 4 [1, 10] 4 [1, 9] 0.55 
PHQ-9 score 9 [4, 15] 8 [4, 14] 0.37 
Aldosterone use 202 (47%) 471 (45%) 0.84 
ACE-inhibitor/ARB use 348 (81%) 868 (83%) 0.31 
Antiarrhythmic medication use 73 (17%) 125 (12%) 0.005 
Beta-blocker use 327 (76%) 805 (77%) 0.74 
*
The sample of patients that was used to developed the risk score of 30-day readmission or death in heart 
failure. 









Table 2. Short-term adverse outcomes in heart failure 
Observed risk of adverse outcomes Original sample* (n=430) 
n (%) 
Validation sample (n=1046) 
n (%) 
p 
Within 30 days Death 38 (9%) 72 (7%) 0.09 
 Readmission 92 (21%) 249 (24%) 0.11 
 Composite outcome 130 (30%) 303 (29%) 0.35 
Within 90 days Death 64 (15%) 135 (13%) 0.15 
 Readmission 185 (43%) 439 (42%) 0.36 
 Composite outcome 224 (52%) 509 (49%) 0.36 
*
The sample of patients that was used to developed the risk score of 30-day readmission or death in 
heart failure. 





Table 3. Estimating risk of 30-day readmission or death in heart failure using the prediction model 
Predictors Value  Coefficient  Score  
NYHA class ..…… × 0.67 = ..……  
MoCA score ..…… × −0.10 = ..…… 
 
Left atrial volume index (ml/m
2
) ..…… × 0.02 = ..…… 
Right atrial pressure (mmHg) ..…… × 0.06 = ..…… 
Discharge in winter (Y=1 vs N=0) ..…… × 0.49 = ..…… 
Living alone (Y=1 vs N=0) ..…… × 0.72 = ..…… 
Blood urea nitrogen (mmol/l) ..…… × 0.04 = ..…… 
PHQ-9 score ..…… × 0.03 = ..…… 
Heart rate (per bpm) ..…… × 0.02 = ..…… 
Albumin (g/dl) ..…… × −0.05 = ..…… 
Life-threatening arrhythmia (Y=1 vs N=0) ..…… × 1.07 = ..…… 
Intercept    = −3.31 
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